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Background: Insulin signaling and Tau protein phosphorylation in the hippocampi of young and old obese Zucker
fa/fa rats and their lean controls were assessed to determine whether obesity-induced peripheral insulin resistance
and aging are risk factors for central insulin resistance and whether central insulin resistance is related to the pathologic
phosphorylation of the Tau protein.
Results: Aging and obesity significantly attenuated the phosphorylation of the insulin cascade kinases Akt
(protein kinase B, PKB) and GSK-3β (glycogen synthase kinase 3β) in the hippocampi of the fa/fa rats. Furthermore,
the hyperphosphorylation of Tau Ser396 alone and both Tau Ser396 and Thr231 was significantly augmented by
aging and obesity, respectively, in the hippocampi of these rats.
Conclusions: Both age-induced and obesity-induced peripheral insulin resistance are associated with central insulin
resistance that is linked to hyperTau phosphorylation. Peripheral hyperinsulinemia, rather than hyperglycemia, appears
to promote central insulin resistance and the Tau pathology in fa/fa rats.
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Insulin resistance (IR) is a state during which a higher
than normal insulin level is required for glucose homeo-
stasis. IR occurs in the periphery and in the brain, where
it has recently been linked to the hyperphosphorylation
of the neuronal cytoskeleton protein Tau [1], which is
symptomatic for Alzheimer’s neurodegeneration. After the
glucose homeostasis is disturbed, an increase in the glucose
level indicates the onset of type-2 diabetes (T2D).
In several clinical studies, T2D was found to increase
the risk of Alzheimer’s disease (AD) [2]. In the postmor-
tem brains of both T2D and sporadic AD patients, central
resistance to insulin was documented by attenuated insu-
lin signaling, namely via a decreased phosphorylation of* Correspondence: maletin@uochb.cas.cz
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unless otherwise stated.the insulin cascade kinases PDK1 (3-phosphoinositide-
dependent protein kinase-1), Akt (protein kinase B, PKB),
and GSK-3β (glycogen synthase kinase 3β), and this effect
was more pronounced in patients with both T2D and AD
[3]. GSK-3β acts as both the insulin cascade kinase and
the primary kinase phosphorylating Tau [4,5]. The phos-
phorylation of Ser9 in GSK-3β by Akt inhibits the kinase
activity of GSK-3β [6,7], and the attenuated phosphoryl-
ation of Ser9 logically increases the kinase activity of
GSK-3β toward Tau. Central insulin resistance is linked to
a hyperphosphorylation of Tau through GSK-3β [8].
Severe hyperinsulinemia and hyperglycemia, as well as
the hyperphosphorylation of Ser199/202, Thr231, and
Ser396 in Tau, were found to increase progressively with
age in the hippocampi of db/db mice with impaired lep-
tin receptor signaling, a rodent model of T2D [9]. An
augmented phosphorylation of Ser396 in the hippocam-
pal Tau of db/db mice was later confirmed by anotheral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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db/db mice with fully developed T2D, changes in the in-
sulin receptors and GSK-3β phosphorylation were not
found [11].
Similar to db/db mice, Zucker fatty fa/fa rats have a
genetically homozygous leptin receptor mutation that re-
sults in leptin dysfunction. Zucker fa/fa rats suffer from
obesity induced by hyperphagia, severe hyperlipidemia,
and hyperinsulinemia, resulting in IR in the liver,
muscle, and adipose tissue [12-14]. The IR in fa/fa
rats is established prior to adulthood, at the age of
7 weeks [15]. Unlike db/db mice, fa/fa rats are normogly-
cemic or have only slightly elevated glucose levels and do
not develop diabetes [12,13].
In this study, insulin signaling and Tau phosphoryl-
ation were followed in the hippocampi of 12- (young)
and 33-week-old (old) obese Zucker fa/fa rats and their
lean controls to verify the hypothesis that peripheral in-
sulin resistance resulting from obesity and/or old age
represents a risk factor for central insulin resistance and
that such possible central IR is linked to the pathologic
phosphorylation of Tau protein. In short, we aimed to
determine whether IR with hyperinsulinemia but normo-
glycemia is associated with a risk of Tau protein path-
ology in the hippocampus.
Results
Metabolic parameters
In old age, both the fa/fa rats and controls developed se-
vere obesity compared with the relevant young controls
(F(1,20) = 466.52; p < 0.001). The fa/fa rats also showed
a significantly higher body weight than did the age-
matched controls (F(1,20) = 236.30; p < 0.001) (Table 1).
As expected, obesity in fa/fa rats resulting from impaired
leptin receptor signaling was manifested by hyperlepti-
nemia; thus, a significant age and fa/fa genotype inter-
action exists (F(1,20) = 12.36; p < 0.01), and a subsequent
Bonferroni post-hoc test revealed an increase in the
plasma leptin levels in young fa/fa rats compared with
young controls (p < 0.01); this increase was more pro-
nounced in old fa/fa rats compared with old controls
(p < 0.001) (Table 1). Obesity was accompanied by
hyperinsulinemia. There were significant effects of the fa/faTable 1 Metabolic parameters of fa/fa (obese) rats and their a
Rats Weight [g] Leptin [ng/ml]
Young control 257 ± 14,17 2,02 ± 1,23
Young fa/fa 386 ± 13,68*** 36,72 ± 5,20**
Old control 457 ± 21,38*** 6,33 ± 1,72
Old fa/fa 683 ± 48,31###, ooo 88,66 ± 32,71###, ooo
Data are mean ± SD, n = 6 animals per group. Significance is *P < 0,05, **P < 0,01 and
using two-way ANOVA, Bonferroni post hoc test.
Significance P<0.05, P<0.01, or P<0.001 is illustrated by one, two, or three symbols,genotype (F(1,20) = 71.66; p < 0.001) and age (F(1,20) = 13.94;
p = 0.001), as well as an age x fa/fa genotype inter-
action (F(1,20) = 7.99; p = 0.01) with plasma insulin. Sig-
nificant hyperinsulinemia in fa/fa rats was represented
by extreme insulin levels that reached 12-fold (p < 0.001) at
12 weeks of age and 9-fold at 33 weeks of age (p < 0.001) in
lean age-matched controls. The glucose levels in all rats
were similar and did not exceed normal values (Table 1).
Quantitative insulin sensitivity check index (QUICKI)
was significantly decreased in both 12-week-old obese
(p < 0.05) and 33-week-old obese rats (p < 0.05) com-
pared to age-matched lean controls. Both age (p = 0.002)
and fa/fa genotype (p = 0.012) were accompanied with
higher and longer lasting rise in glycaemia during glucose
tolerance test as revealed by general linear model for re-
peated measures. However, there was no interaction be-
tween these factors (Figure 1). The impairment in glucose
tolerance was assessed also using parameter of 2-h gly-
cemia during IPGTT. This impairment was observed
with respect to age (F(1,20) = 19.30; p < 0.001) as well as
to fa/fa genotype (F(1,20) = 21.44; p < 0.001). There was
no detected effect of an age x fa/fa genotype inter-
action. The area under the curve of the glucose level
during IPGTT was found to increase due only to the
fa/fa genotype (F(1,20) = 5.41; p < 0.05).
Dyslipidemia in young and old fa/fa rats was noticed
based on the serum lipid parameters. Both total choles-
terol (F(1,20) = 120.38; p < 0.001) and cholesterol/HDL ra-
tio (F(1,20) = 23.55; p < 0.001) were significantly increased
in fa/fa rats compared with lean rats (Table 2). Statistical
analysis also revealed that age significantly affected the
plasma total cholesterol (F(1,20) = 58.30; p < 0.001) and
cholesterol/HDL ratio (F(1,20) = 4.38; p < 0.05). A signifi-
cant age x fa/fa genotype interaction significantly affects
the plasma total cholesterol (F(1,20) = 42.83; p < 0.001)
and cholesterol/HDL ratio (F(1,20) = 6.26; p < 0.05). As re-
vealed in the post-hoc test, both the plasma total choles-
terol were significantly increased in young and old fa/fa
rats compared with their age-matched lean controls
(p < 0.001). An age-dependent increase in this lipid
parameter was observed only in fa/fa rats (p < 0.001).
The cholesterol/HDL ratio was increased in old fa/fa rats
compared with their lean age-matched rats (p < 0.001) andge matched controls
Insulin [ng/ml] Glucose [mmol/l] QUICKI
0,50 ± 0,24 6,00 ± 0,42 0,537 ± 0,071
6,26 ± 2,14** 6,27 ± 0,63 0,234 ± 0,008*
1,43 ± 0,38 6,38 ± 0,43 0,274 ± 0,010
12,96 ± 4,50###, ooo 6,80 ± 0,51 0,216 ± 0,007o
***P < 0,001 (*vs. young control rats, #vs. young fa/fa rats, ovs. old control rats)
respectively. Particular symbols are for particular groups compared.
Figure 1 Graph of inraperitoneal glucose tolerance test. Before
the IPGTT rats were fasted overnight. The intraperitoneal injection of
50% dextrose at dose 2 g/kg was administered and glucose was
measured in the tail vein using a glucometer. Data are mean ± SD
(n = 6 rats per group). Statistical analysis was calculated by two-way
ANOVA, Bonferroni post hoc test.
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plasma triglycerides levels, a significant elevation was no-
ticed only in 33-week-old obese Zucker rats compared to
lean rats of the same age.
Insulin signaling cascade in the hippocampus
Regarding the insulin cascade, a two-way ANOVA re-
vealed a significant main effect of the fa/fa genotype
(F(1,20) = 6.82; p < 0.05) on insulin receptor protein ex-
pression. In Zucker fatty rats, obesity was associated
with lower hippocampal insulin receptor protein levels
(Figure 2). However, aging did not affect hippocampal
insulin receptor protein expression (F(1,20) = 0.43; p < 0.52).
There was no significant interaction between age and
genotype (F(1,20) = 0.78; p < 0.08).
Age had a main effect on decreasing the level of
PI3 kinase (PI3K) (F(1,20) = 42.03; p < 0.001). The level
of PI3K was also attenuated due to the fa/fa pheno-
type (F(1,20) = 9.84; p < 0.001) (Figure 2). The two-way
ANOVA revealed a significant interaction between age andTable 2 Levels of lipids in blood serum of fa/fa (obese)






Young control 2,25 ± 0,23 0,783 ± 0,117 1,605 ± 0,066
Young fa/fa 3,40 ± 0,41** 2,917 ± 0,703 1,988 ± 0,214
Old control 2,53 ± 0,15 0,783 ± 0,098 1,539 ± 0,067
Old fa/fa 7,08 ± 1,17###, ooo 4,000 ± 0,802oo 2,736 ± 0,763##, ooo
Data are mean ± SD, n = 6 animals per group. Significance is *P < 0,05, **P < 0,01
and ***P < 0,001 (*vs. young control rats, #vs. young fa/fa rats, ovs. old control rats)
using two-way ANOVA, Bonferroni post hoc test.
Significance P<0.05, P<0.01, or P<0.001 is illustrated by one, two, or three
symbols, respectively. Particular symbols are for particular groups compared.genotype (F(1,20) = 17.77; p < 0.001). Bonferroni’s post-hoc
test revealed significantly decreased levels of PI3K in young
obese rats compared with young lean rats (p < 0.001) and
in old lean rats compared with young lean rats (p < 0.001).
No significant differences were observed between old obese
and old lean rats.
As determined by the two-way ANOVA, there was
significant main effect of fa/fa genotype (F(1,20) = 5.00;
p < 0.05) on the phosphorylation of PDK1 Ser241 in
the hippocampus (Figure 2). Obesity decreased PDK1
Ser241 phosphorylation in the hippocampi of Zucker
fa/fa rats. Neither a significant main effect of age nor
an interaction between age and genotype was detected
(Figure 2).
The two-way ANOVA revealed a significant main effect
of age (F(1,20) = 27.11; p < 0.001) on the phosphorylation of
Akt Thr308 (Figure 2). Aging significantly attenuated the
hippocampal phosphorylation of Akt Thr308 in both fa/fa
and lean rats. Neither a significant effect of genotype
(F(1,20) = 0.67; p < 0.42) nor an interaction between age
and genotype (F(1,20) = 1.80; p < 0.19) was noted. Regard-
ing the phosphorylation of Akt Ser473, significant main
effects of age (F(1,20) = 31.10; p < 0.001) and the fa/fa geno-
type (F(1,20) = 6.51; p < 0.05) were observed. Both aging and
obesity attenuated the phosphorylation of Akt Ser473
(Figure 2). There was no significant interaction between
age and the fa/fa genotype (F(1,20) = 1.08; p < 0.31).
Similarly, significant main effects of age (F(1,20) = 9.84;
p < 0.01) and the fa/fa genotype (F(1,20) = 12.26; p < 0.01)
(Figure 2) on the phosphorylation of GSK-3β Ser9 were
observed. Both aging and obesity reduced the phosphor-
ylation of GSK-3β Ser9 (Figure 2). No significant inter-
action between these factors was detected (F(1,20) = 0.81;
p < 0.38).
Abnormal phosphorylation of tau protein in the
hippocampus
Regarding the phosphorylation of tau at Ser396 in
the hippocampus, main effects of age (F(1,20) = 21.55;
p < 0.001) and genotype (F(1,20) = 31.16; p < 0.001) were
found. Both of these factors increased the phosphorylation
of hippocampal tau at Ser396 (Figure 3). There was no sig-
nificant interaction between age and the fa/fa genotype
(F(1,20) = 1.35; p < 0.26). The two-way ANOVA revealed a
significant main effect of fa/fa genotype (F(1,20) = 8.86;
p < 0.01) on Tau Thr231 phosphorylation (Figure 3).
Obesity significantly increased the phosphorylation of
hippocampal Tau Thr231. Neither a significant effect of
age (F(1,20) = 0.21; p < 0.66) nor an interaction between
age and genotype (F(1,20) = 0.05; p < 0.82) was noted.
Discussion and conclusions
This study revealed attenuated insulin signaling and in-
creased hyperphosphorylation of Tau (at Ser396 and
Figure 2 Insulin signaling cascade in hippocampi of fa/fa rats and their control. A Western blots of the proteins involved in insulin
signaling cascade using specific antibodies (n = 6 rats per group) B Densitometric quantification of the western blots normalized to beta-actin:
data are mean ± SD (n = 6 rats per group). Statistical analysis was calculated by two-way ANOVA, Bonferroni post hoc test.
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ipheral insulin resistance or advanced age.
Both the fa/fa rats in this study and the db/db mice in
a previous work [9] exhibited impaired leptin signaling,
hyperinsulinemia and blood insulin levels approximately
10-fold higher than the normal values. These data indi-
cate that peripheral insulin resistance developed at an
early age (8 and 12 weeks) in the db/db mice and the fa/fa
rats, respectively. IR in the fa/fa rats was indirectly demon-
strated using the QUICKI test. Dyslipidemia in the fa/fa
rats could be linked to peripheral IR.
The fa/fa rats were normoglycemic even at an ad-
vanced age (33 weeks), whereas 8-week-old db/db mice
had glucose levels double those of the control db +mice
[9]. Glucose or glucosamine availability is considered todetermine the degree of GlcNAcylation of the serines
and threonines in the Tau protein that can be phosphor-
ylated [16]. The attenuation of GlcNAcylation in favor of
the augmented phosphorylation of the Tau protein has
been described as a possible mechanism of Tau path-
ology [17-19]. On the other hand, healthy mice deprived
of food for one to three days (which likely resulted in
lower than normal glucose levels) exhibited reversible
phosphorylation of hippocampal Tau Ser396 [20]. The
fa/fa rats in the present study exhibited an obvious
increase in the hyperphosphorylation of hippocampal
Tau protein in the normoglycemic state. This finding
supports the hypothesis that insulin ineffectiveness,
rather than extreme glucose levels, is linked to Tau
hyperphosphorylation.
Figure 3 Hyperphosphorylation of Tau protein on different epitopes in hippocampi of fa/fa rats and their control. A Western blots of
phosphorylation of Tau protein on the epitopes Ser396 and Thr231 (n = 6 rats per group) B Densitometric quantification of western blots
normalized to β-actin: data are mean ± SD (n = 6 rats per group). Statistical analysis was calculated by two-way ANOVA, Bonferroni post hoc test.
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hippocampal levels of insulin receptor and PI3 kinase
protein. Statistically significantly attenuated phosphoryl-
ation of both Akt Thr308 and Ser473 was detected
in old-age rats, and this effect was more pronounced in
fa/fa rats. A similar trend was found for the phosphoryl-
ation of Ser9 in GSK3/β. GSK-3β, a kinase common in
insulin cascading and Tau phosphorylation, is constitu-
tively active in resting neurons, and its activity is nega-
tively affected by Ser9 phosphorylation [6,7]. GSK-3β
is the primary Tau kinase that hyperphosphorylates
Tau [21-23], with Ser199, Thr231, Ser396, and Ser413
as the predominant targets [24]. Cavallini et al. [25]
identified GSK-3β and also GSK-3α and MAPK13 as
the most active out of 352 kinases overexpressing both
Tau kinases and Tau protein [25]. Besides Akt and
GSK-3β, extracellular signal-regulated kinase (ERK), is
involved both in insulin signaling and Tau phosphor-
ylation. However, there were found no differences in
ERK1/2 phosphorylation between the groups in this
study (not shown).
The Ser396 and Thr231 phosphorylations investigated
in this study are essential in Tau protein pathology for
the following reasons. Ser396 is directly phosphorylated
by GSK-3β without priming (previous phosphorylation
of another Ser or Thr on the Tau protein) [26]. More-
over, a positive relationship between the phosphorylationof Tau Ser396 in the cerebrospinal fluid and the sever-
ity of the disease was found in AD patients [27]. Add-
itionally, NIRCO (neuron specific knock-out) mice
without insulin receptors in brain neurons showed an
increase in the phosphorylation of Tau Thr231, which
resulted from the attenuated phosphorylation of Akt
Ser473 and GSK-3β Ser9 [5]. Cavallini et al. [25] speci-
fied the main phosphorylation sites of Tau as Ser202,
Thr231, Ser235, and Ser396/404. In addition to Ser396
and Thr231, we examined Tau phosphorylation at Ser212/
214 and Ser 202 in all the groups, but the results were
inconsistent.
Inefficient leptin signaling in fa/fa rats could con-
tribute to Tau hyperphosphorylation because leptin
has been reported to prevent Tau phosphorylation in
neuronal cells via the activation of AMP-dependent
kinase [28]. This process was later found to be stress
dependent [29], making its role in Tau pathology
unclear.
This study demonstrated that the phosphorylation
of Ser396 and Thr231 in hippocampal Tau was related
to the fa/fa obese phenotype; an interaction with the
rats’ age was found for Ser396 only. Analogously, in
the hippocampi of db/db mice with non-functioning
leptin receptors and severe IR, Tau phosphorylation at
Ser 199/202, Thr231, and Ser396 was found to pro-
gress with age. Unfortunately, the previous study of
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insulin signaling.
In a human study [3], attenuated insulin signaling
was inversely correlated with increased Tau hyperpho-
sphorylation in the frontal cortex of T2D patients, and
this correlation was more pronounced in T2D patients
with AD co-morbidity. However, data on insulin, glu-
cose, and lipid levels were not accessible because of
postmortem sampling. Nevertheless, both impaired in-
sulin signaling and Tau hyperphosphorylation in the
brain were obvious in both the human study [3] and
this rat study.
Peripheral IR in old-age rats appeared to result in
central insulin resistance and Tau hyperprotein phos-
phorylation in the hippocampus. This effect was more
pronounced in obese fa/fa rats, which are prone to
obesity-induced IR. Based on the normoglycemic state
of the IR fa/fa rats, we conclude that a pre-T2D state
with IR and normoglycemia is associated with an in-
creased risk of central pathological IR and Tau phos-
phorylation. The precise mechanism and the role of
leptin signaling should be elucidated.
Methods
Animals
This investigation was conducted in accordance with eth-
ical standards of the Declaration of Helsinki. This study
conformed to national and international guidelines and
was approved by the authors’ institutional review board.
All experimental procedures and animal care were car-
ried out according to the Jagiellonian University Ethical
Committee on Animal Experiments (No 75/2011).
Old (33 weeks old) and young (12 weeks old) male
obese Zucker fa/fa rats and their age-matched lean con-
trols (n = 6 per each group) were maintained at Jagellonian
University in Krakow, Poland. Lean individuals (dominant
homozygotes Fa/Fa or heterozygotes Fa/fa) served as lean
controls for the obese fa/fa rats. The animals had free
access to food and water.
The overnight-fasted rats were euthanized by decapita-
tion. The blood glucose was measured at Synlab (Bratislava,
Slovakia) using the multi-analyzer COBAS Integra
800 (Roche Diagnostics Ltd., Rotkreuz, Switzerland), and
the serum leptin and insulin levels were determined
using RIA kits (Millipore, USA) following the manufac-
turer’s instructions. The measurements of the serum
lipids were performed in the Laboratory Diagnostics
Unit of The University Hospital in Krakow using com-
mercially available kits (Roche Molecular Diagnostics,
Pleasanton, CA, USA). The quantitative insulin sensi-
tivity check index (QUICKI) [30] was calculated as
QUICKI = 1/[(log(I0) + log(G0)], where I0 is the fasting
plasma insulin level (microunits per mL), and G0 is the
fasting blood glucose level (milligrams per dL).Intraperitoneal glucose tolerance test
All rats were subjected to an intraperitoneal glucose tol-
erance test (IPGTT) 2 days prior to euthanasia and after
a 16-hour-long overnight fast. The rats were adminis-
tered an intraperitoneal injection of 50% dextrose at a
dose of 2 g/kg body weight. The blood glucose was mea-
sured using a glucometer (Accu-Chek Active, Roche
Diagnostics, Germany) in the tail vein blood prior to and
30, 60, 90, and 120 min after glucose administration.
Tissue preparation for western blotting
The dissected hippocampi were homogenized in a glass
microhomogenizer using lysis buffer (62.5 mM Tris–
HCl buffer with pH 6.8, 1% deoxycholate, 1% Triton
X-100, 50 mM NaF, 1 mM Na3VO4, and Complete
Protease Inhibitor (Roche, Switzerland). The lysates
were sonicated for 10 min and boiled for 10 minutes.
The samples for electrophoresis at 1 μg/μl were diluted
with a Laemmli sample buffer containing 50 mM NaF
and 1 mM Na3VO4.
Antibodies
The following primary antibodies were used: insulin re-
ceptor rabbit mAb, PI3 kinase rabbit Ab, phospho-PDK1
(Ser241) rabbit mAb, PDK1 rabbit mAb, phospho-Akt
(Thr308) rabbit mAb, phospho-Akt (Ser473) rabbit
mAb, Akt rabbit mAb, phospho-GSK-3β (Ser9) rabbit
mAb, and GSK-3 β rabbit mAb (all from Cell Signaling
Technology, Beverly, MA, USA); phosphoTau (Ser396)
rabbit mAb and phosphoTau (Thr231) rabbit mAb (clone
PHF13.6 and PHF-6, respectively, both from Invitrogen,
NY, USA); CTer mouse mAb for total Tau protein (gift
from Dr. M.-C. Galas, Inserm U837, Lille, France); and
beta-actin mouse mAb (from Sigma Aldrich). The follow-
ing secondary antibodies were used: anti-mouse IgG HRP-
linked antibody and anti-rabbit IgG HRP-linked antibody
(both from Cell Signaling Technology, Beverly, MA, USA).
Western blotting
Samples of 2–15 μg total protein were subjected to 4/10%
SDS-PAGE and transferred onto nitrocellulose (BIO-RAD)
or polyvinylidene difluoride (Sigma Aldrich) membranes.
The blots were blocked in 5% non-fat milk or 3% BSA in a
TBS/Tween buffer (20 mM Tris, 136 mM NaCl, 0.1%
Tween-20) with 50 mM NaF and 1 mM Na3VO4, incu-
bated with the appropriate primary antibody, then incu-
bated with the HRP-linked secondary antibody and
developed using the SuperSignal West Femto maximum
sensitivity substrate (Pierce, Rockford, IL, USA) following
the manufacturer’s instructions. The bands were visualized
using the ChemiDoc™ System (BIO-RAD, Hercules, CA,
USA) and were quantified using Image Lab Software
(BIO-RAD, Hercules, CA, USA). The band intensities were
normalized using actin as an internal loading compound,
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phorylated protein and the intensity of the band with the
total level of protein were calculated.
Statistical analysis
The data were analyzed using IBM SPSS 19 Software
and are presented as the means ± SD. The data were
tested for normality by Shapiro-Wilk test. Normally
distributed data were analysed by two-way analysis of
variance with interaction with factors of age and fa/fa
genotype. Non-normally distributed data were subjected
to natural logarithm transformation followed by two-
way ANOVA (insulin). Data without normal distribution
despite the use of above mentioned transformation were
analysed by non-parametric Kruskal-Wallis test (QUICKI,
triglycerides). General Linear Model for Repeated Measures
was used to evaluate differences in glycaemia during
IPGTT. Total area under the curve (AUC) was calculated
to describe increment of plasma glucose levels after ex-
ogenous glucose load. The overall level of statistical signifi-
cance was p < 0.05.
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